Wall Street brokerages expect Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) to announce sales of $2.98 billion for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Regeneron Pharmaceuticals’ earnings, with the highest sales estimate coming in at $4.30 billion and the lowest estimate coming in at $2.55 billion. Regeneron Pharmaceuticals reported sales of $2.53 billion during the same quarter last year, which would suggest a positive year over year growth rate of 17.8%. The firm is expected to issue its next earnings report before the market opens on Monday, January 1st.
On average, analysts expect that Regeneron Pharmaceuticals will report full year sales of $11.70 billion for the current financial year, with estimates ranging from $11.18 billion to $12.11 billion. For the next financial year, analysts anticipate that the firm will report sales of $12.51 billion, with estimates ranging from $10.82 billion to $13.78 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last posted its earnings results on Friday, February 4th. The biopharmaceutical company reported $23.72 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $18.49 by $5.23. The company had revenue of $4.95 billion for the quarter, compared to analyst estimates of $4.49 billion. Regeneron Pharmaceuticals had a net margin of 50.24% and a return on equity of 55.11%. The business’s revenue for the quarter was up 104.4% compared to the same quarter last year. During the same period last year, the business posted $8.72 earnings per share.
In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 1st. The shares were sold at an average price of $607.46, for a total transaction of $607,460.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,240 shares of the firm’s stock in a transaction on Thursday, April 7th. The shares were sold at an average price of $725.00, for a total transaction of $899,000.00. Following the sale, the director now owns 1,082 shares in the company, valued at approximately $784,450. The disclosure for this sale can be found here. Insiders sold a total of 44,459 shares of company stock worth $30,177,797 over the last quarter. Corporate insiders own 11.84% of the company’s stock.
Several institutional investors have recently bought and sold shares of REGN. Heritage Wealth Advisors purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $30,000. Benjamin Edwards Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $33,000. Delos Wealth Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $33,000. Byrne Asset Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $34,000. Finally, Evoke Wealth LLC grew its holdings in shares of Regeneron Pharmaceuticals by 427.3% during the 3rd quarter. Evoke Wealth LLC now owns 58 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.
REGN traded up $1.13 during mid-day trading on Monday, hitting $733.02. The stock had a trading volume of 795,710 shares, compared to its average volume of 697,631. The stock’s fifty day simple moving average is $660.49 and its 200-day simple moving average is $631.01. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.56 and a quick ratio of 3.07. The firm has a market capitalization of $78.83 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 1.25 and a beta of 0.21. Regeneron Pharmaceuticals has a 1-year low of $478.40 and a 1-year high of $747.42.
Regeneron Pharmaceuticals Company Profile (Get Rating)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Regeneron Pharmaceuticals (REGN)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.